Roche Hldg Ltd Spons (RHHBY) 32.0900 $RHHBY
Roche (RHHBY) Misses on Q2 Revenues, New Launches in Focus
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 5:32PM CDT
Roche Holding (RHHBY) reported sales of $12.1 billion in the second quarter of 2016, missing the Zacks Consensus Estimate of $12.9 billion.
JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), ABBV: 66.23 (+1.51)
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
Sheraz Mian - Zacks Investment Research - Mon Jul 25, 1:23PM CDT
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
BIIB: 289.93 (+0.90), RCI: 44.17 (+0.54), T: 43.29 (+0.71), PHM: 21.18 (-0.54), INTC: 34.86 (+0.09), SYK: 116.28 (+1.32)
Roche's Gazyva Fails in Phase III B-cell Lymphoma Study
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:42PM CDT
Roche Holding AG (RHHBY) announced disappointing results from the phase III study on Gazyva.
JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), PFE: 36.89 (+0.22)
Novartis' Enbrel Biosimilar Gets FDA Panel Recommendation
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:06AM CDT
Novartis AG (NVS) announced that the FDA's Arthritis Advisory Committee has recommended an approval of the company's proposed biosimilar of Amgen's (AMGN) blockbuster drug, Enbrel (etanercept).
JNJ: 125.23 (+0.77), AMGN: 172.03 (+0.75), NVS: 83.26 (+1.18)
Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:16AM CDT
Amgen (AMGN) inked an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan.
AMGN: 172.03 (+0.75), ABBV: 66.23 (+1.51), NVS: 83.26 (+1.18)
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), PFE: 36.89 (+0.22)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 125.23 (+0.77), PFE: 36.89 (+0.22), SCMP: 11.75 (+0.07)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 125.23 (+0.77), PFE: 36.89 (+0.22), NVS: 83.26 (+1.18)
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:28AM CDT
Puma Biotechnology (PBYI) reported the publication of phase II study (I-SPY 2) data on neratinib for the neoadjuvant treatment of breast cancer.
INVA: 12.87 (+1.17), PFE: 36.89 (+0.22), PBYI: 49.89 (+1.37)
FDA Approves Genentech's Xolair(R) (omalizumab) for Allergic Asthma in Children
BusinessWire - Thu Jul 07, 3:40PM CDT
--Asthma is one of the most common long-term diseases in children(1), affecting about 6.3 million people younger than 18 in the U.S.(2 )
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 60.60 (+0.99), PFE: 36.89 (+0.22), EPZM: 10.36 (+0.10)
Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 36.89 (+0.22), BMY: 74.81 (+0.15), EXEL: 9.18 (+0.23)
Phase III Study Shows Genentech's Actemra(R) (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)
BusinessWire - Mon Jun 06, 11:53AM CDT
--There have been no new treatments for GCA in more than 50 years
Genentech's Cancer Immunotherapy TECENTRIQ(TM) (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
BusinessWire - Sun Jun 05, 6:30AM CDT
--TECENTRIQ is the first and only cancer immunotherapy approved to treat bladder cancer
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.19 (+0.02), TEVA: 53.50 (-1.29), GSK: 45.07 (-0.11)
Roche's Subcutaneous Formulation of MabThera Gets EU Nod
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Roche (RHHBY) announced that the EC has approved the subcutaneous formulation of MabThera (rituximab) for the treatment of patients suffering from previously untreated and relapsed/refractory CLL.
BIIB: 289.93 (+0.90), PFE: 36.89 (+0.22), BMY: 74.81 (+0.15)
Watch for Roche Holding to Potentially Pullback After Gaining 3.64% Yesterday
Comtex SmarTrend(R) - Fri May 27, 1:36PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $33.20 to a high of $33.41. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $32.15 on volume of 795,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Genentech's Gazyva(R) Showed Superior Progression-Free Survival Compared to Rituxan(R) in People with Previously Untreated Follicular Lymphoma
BusinessWire - Fri May 27, 12:00AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin's lymphoma (iNHL). The study compared the efficacy and safety of Gazyva(R) (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan(R) (rituximab) plus chemotherapy followed by Rituxan alone. Results from a pre-planned interim analysis showed that Gazyva-based treatment significantly reduced the risk of disease worsening or death (progression-free survival; PFS, as assessed by investigator) compared to Rituxan-based treatment. Adverse events with either Gazyva or Rituxan were consistent with what was seen in previous clinical trials when each was combined with various chemotherapies. Data from the GALLIUM study will be presented at an upcoming medical meeting and submitted to health authorities for approval consideration.
Roche (RHHBY) Misses on Q2 Revenues, New Launches in Focus
Zacks Equity Research - Zacks Investment Research - Mon Jul 25, 5:32PM CDT
Roche Holding (RHHBY) reported sales of $12.1 billion in the second quarter of 2016, missing the Zacks Consensus Estimate of $12.9 billion.
JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), ABBV: 66.23 (+1.51)
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
Sheraz Mian - Zacks Investment Research - Mon Jul 25, 1:23PM CDT
Fresh Research Reports For Intel (INTC), AT&T (T) & Others
BIIB: 289.93 (+0.90), RCI: 44.17 (+0.54), T: 43.29 (+0.71), PHM: 21.18 (-0.54), INTC: 34.86 (+0.09), SYK: 116.28 (+1.32)
Roche's Gazyva Fails in Phase III B-cell Lymphoma Study
Zacks Equity Research - Zacks Investment Research - Mon Jul 18, 5:42PM CDT
Roche Holding AG (RHHBY) announced disappointing results from the phase III study on Gazyva.
JNJ: 125.23 (+0.77), GILD: 79.47 (-1.77), PFE: 36.89 (+0.22)
Novartis' Enbrel Biosimilar Gets FDA Panel Recommendation
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 11:06AM CDT
Novartis AG (NVS) announced that the FDA's Arthritis Advisory Committee has recommended an approval of the company's proposed biosimilar of Amgen's (AMGN) blockbuster drug, Enbrel (etanercept).
JNJ: 125.23 (+0.77), AMGN: 172.03 (+0.75), NVS: 83.26 (+1.18)
Amgen and Daiichi Sankyo Team Up for Biosimilars in Japan
Zacks Equity Research - Zacks Investment Research - Thu Jul 14, 9:16AM CDT
Amgen (AMGN) inked an exclusive agreement with Daiichi Sankyo for the commercialization of nine biosimilars in Japan.
AMGN: 172.03 (+0.75), ABBV: 66.23 (+1.51), NVS: 83.26 (+1.18)
Pfizer (PFE) Gets FDA Nod for Label Expansion of Prevnar 13
Zacks Equity Research - Zacks Investment Research - Wed Jul 13, 8:25AM CDT
Pfizer Inc. (PFE) announced that the FDA has approved a label expansion of vaccine Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]).
ABT: 44.75 (+0.30), JNJ: 125.23 (+0.77), PFE: 36.89 (+0.22)
Sucampo to Stop Developing Cobiprostone for Oral Mucositis
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:28PM CDT
Sucampo Pharmaceuticals, Inc. (SCMP) announced that it will discontinue the development of its pipeline candidate, cobiprostone.
JNJ: 125.23 (+0.77), PFE: 36.89 (+0.22), SCMP: 11.75 (+0.07)
Shire's (SHPG) Dry Eye Disease Drug Xiidra Gets FDA Nod
Zacks Equity Research - Zacks Investment Research - Tue Jul 12, 7:20PM CDT
Shire plc (SHPG) received a major boost when the FDA approved its ophthalmology drug Xiidra for the treatment of the signs and symptoms of dry eye disease in adults.
JNJ: 125.23 (+0.77), SHPG: 194.12 (+2.69), PFE: 36.89 (+0.22)
Roche Asthma Drug Xolair Gets FDA Nod for Label Expansion
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 5:23PM CDT
Roche Holding AG (RHHBY) announced that the FDA has approved a label expansion of respiratory drug, Xolair.
JNJ: 125.23 (+0.77), PFE: 36.89 (+0.22), NVS: 83.26 (+1.18)
Puma (PBYI) Stock Up, Phase II Data on Neratinib Published
Zacks Equity Research - Zacks Investment Research - Fri Jul 08, 10:28AM CDT
Puma Biotechnology (PBYI) reported the publication of phase II study (I-SPY 2) data on neratinib for the neoadjuvant treatment of breast cancer.
INVA: 12.87 (+1.17), PFE: 36.89 (+0.22), PBYI: 49.89 (+1.37)
FDA Approves Genentech's Xolair(R) (omalizumab) for Allergic Asthma in Children
BusinessWire - Thu Jul 07, 3:40PM CDT
--Asthma is one of the most common long-term diseases in children(1), affecting about 6.3 million people younger than 18 in the U.S.(2 )
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 60.60 (+0.99), PFE: 36.89 (+0.22), EPZM: 10.36 (+0.10)
Roche Presents Encouraging Data on Actemra and Tecentriq
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 3:49PM CDT
Roche Holding AG (RHHBY) announced positive results from the phase III study, GiACTA, on arthritis drug, Actemra/RoActemra.
PFE: 36.89 (+0.22), BMY: 74.81 (+0.15), EXEL: 9.18 (+0.23)
Phase III Study Shows Genentech's Actemra(R) (tocilizumab) Maintained Steroid-Free Remission in People With Giant Cell Arteritis (GCA)
BusinessWire - Mon Jun 06, 11:53AM CDT
--There have been no new treatments for GCA in more than 50 years
Genentech's Cancer Immunotherapy TECENTRIQ(TM) (Atezolizumab) Shrank Tumors in People with Previously Untreated Advanced Bladder Cancer
BusinessWire - Sun Jun 05, 6:30AM CDT
--TECENTRIQ is the first and only cancer immunotherapy approved to treat bladder cancer
Promising Lupus Drug From XTL Biopharmaceuticals Could Be Life Changer In Projected $4 Billion Market
ACCESSWIRE - Thu Jun 02, 8:01AM CDT
NEW YORK, NY / ACCESSWIRE / June 2, 2016 / Lupus - invisible, silent; an autoimmune disease where the body's defenses mistakenly attack its own cells and living with lupus is never ending. Up to 5 million people, mainly women of childbearing age, suffer progression of this disorder because of diagnostic confusion. Most present with fever, malaise and facial skin rash suggesting to internists other unrelated health problems. A capricious disease, lupus strikes in skin, joints, kidney, heart, pancreas, colon, eyes, blood...the list continues and flare-ups are sporadic. If organ damage is severe, lupus can be fatal.
XTLB: 1.19 (+0.02), TEVA: 53.50 (-1.29), GSK: 45.07 (-0.11)
Roche's Subcutaneous Formulation of MabThera Gets EU Nod
Zacks Equity Research - Zacks Investment Research - Tue May 31, 9:10AM CDT
Roche (RHHBY) announced that the EC has approved the subcutaneous formulation of MabThera (rituximab) for the treatment of patients suffering from previously untreated and relapsed/refractory CLL.
BIIB: 289.93 (+0.90), PFE: 36.89 (+0.22), BMY: 74.81 (+0.15)
Watch for Roche Holding to Potentially Pullback After Gaining 3.64% Yesterday
Comtex SmarTrend(R) - Fri May 27, 1:36PM CDT
Roche Holding (NASDAQ:RHHBY) traded in a range yesterday that spanned from a low of $33.20 to a high of $33.41. Yesterday, the shares gained 3.6%, which took the trading range above the 3-day high of $32.15 on volume of 795,000 shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Genentech's Gazyva(R) Showed Superior Progression-Free Survival Compared to Rituxan(R) in People with Previously Untreated Follicular Lymphoma
BusinessWire - Fri May 27, 12:00AM CDT
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the pivotal Phase III GALLIUM study in people with previously untreated follicular lymphoma, the most common type of indolent (slow-growing) non-Hodgkin's lymphoma (iNHL). The study compared the efficacy and safety of Gazyva(R) (obinutuzumab) plus chemotherapy (CHOP, CVP or bendamustine) followed by Gazyva alone, head-to-head with Rituxan(R) (rituximab) plus chemotherapy followed by Rituxan alone. Results from a pre-planned interim analysis showed that Gazyva-based treatment significantly reduced the risk of disease worsening or death (progression-free survival; PFS, as assessed by investigator) compared to Rituxan-based treatment. Adverse events with either Gazyva or Rituxan were consistent with what was seen in previous clinical trials when each was combined with various chemotherapies. Data from the GALLIUM study will be presented at an upcoming medical meeting and submitted to health authorities for approval consideration.
